Swedish Orphan Biovitrum AB (publ)
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Guido Oelkers
- Full Time Employees
- 1,969
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Tomtebodavägen 23A Solna Sweden 112 76
- IPO Date
- Jan 8, 2021
- Website
- sobi.com
- Similar Companies
- Business
- Swedish Orphan Biovitrum AB (publ) (Sobi) specializes in rare diseases, developing, manufacturing and commercializing specialty pharmaceuticals in haematology, immunology and specialty care; core products include Alprolix and Elocta (now transitioning to Altuvoct) for haemophilia A and B, Doptelet (avatrombopag) for thrombocytopenia in chronic liver disease and immune thrombocytopenia, Kineret (anakinra) for cryopyrin-associated periodic syndromes and rheumatoid arthritis, Gamifant (emapalumab) for primary haemophagocytic lymphohistiocytosis, Aspaveli (pegcetacoplan) for paroxysmal nocturnal haemoglobinuria, Vonjo (pacritinib) for myelofibrosis, Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma, Kepivance (palifermin) for oral mucositis, Synagis (palivizumab) for respiratory syncytial virus prevention and partner products across haematology, oncology and emergency care; the company also manufactures active components for ReFacto. Founded in 2001 and headquartered in Stockholm, Sweden, Sobi operates globally across Europe, North America, the Middle East, Asia and Australia with subsidiaries in multiple countries including Denmark, Finland, Norway, the United Kingdom and France. In recent developments, Sobi launched Altuvoct (efanesoctocog alfa) for haemophilia A, achieving 57% market share in Germany within nine months and strong growth across launched markets including Switzerland and Spain, while reporting robust revenue increases in 2025 with total revenue up 13% to SEK 6.2 billion in Q2 and haematology sales up 27% driven by Doptelet, Aspaveli and Altuvoct; the company relocated to a new global headquarters in Hagastaden, Stockholm, advanced Gamifant label expansion with FDA priority review and maintained focus on organic growth without major acquisitions.
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call Transcript
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript
Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS)
Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call Transcript
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Trading 1.1% Higher – What’s Next?
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) - Special Call
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call Transcript
Swedish Orphan Biovitrum: Haematology Focus Seems To Be Paying Off
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Transcript
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2024 Earnings Call Transcript
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript